Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. - Wikidata - wikimedia - TriplyDB

Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.

Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.

http://www.wikidata.org/entity/Q33184179

about

Bacterial Cytosine Deaminase Mutants Created by Molecular Engineering Show Improved 5-Fluorocytosine-Mediated Cell Killing In vitro and In vivo Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo.Advances in preclinical investigation of prostate cancer gene therapy.Engineering Kinases to Phosphorylate Nucleoside Analogs for Antiviral and Cancer Therapy.Prodrug activation by Cryptosporidium thymidine kinase.Adenoviral vector-mediated gene therapy for gliomas: coming of age.Thymidine kinase suicide gene-mediated ganciclovir ablation of autologous gene-modified rhesus hematopoiesis.HSV-TK/GCV cancer suicide gene therapy by a designed recombinant multifunctional vector.Rapamycin enhances adenovirus-mediated cancer imaging and therapy in pre-immunized murine hosts Destruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells.Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas Horizontally acquired genes in early-diverging pathogenic fungi enable the use of host nucleosides and nucleotides The role of herpes simplex virus-1 thymidine kinase alanine 168 in substrate specificity.Directed evolution of an orthogonal nucleoside analog kinase via fluorescence-activated cell sorting.Novel application of lentiviral vectors towards treatment of graft-versus-host disease.Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy.Engineering mammalian cells to seek senescence associated secretory phenotypes.Role of Equilibrative Nucleobase Transporter 1/SLC43A3 as a Ganciclovir Transporter in the Induction of Cytotoxic Effect of Ganciclovir in a Suicide Gene Therapy with Herpes Simplex Virus Thymidine Kinase.Conditional Cytotoxic Anti-HIV Gene Therapy for Selectable Cell Modification.An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.Enzyme/Prodrug Systems for Cancer Gene Therapy.Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: the advantage of a cell-specific transcriptional targeting approach.Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle.Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy.Elimination of proliferating cells from CNS grafts using a Ki67 promoter-driven thymidine kinase.Cytoplasmically retargeted HSV1-tk/GFP reporter gene mutants for optimization of noninvasive molecular-genetic imaging.A method for quantification of nucleotides and nucleotide analogues in thymidine kinase assays using lanthanum phosphate coprecipitation.Characterization of an immuno 'stealth' derivative of the herpes simplex virus thymidine-kinase gene.Functional expression of thymidine kinase in human leukaemic and colorectal cells, delivered as EGFP fusion protein by herpesvirus saimiri-based vector.Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation.Introduction of Exogenous HSV-TK Suicide Gene Increases Safety of Keratinocyte-Derived Induced Pluripotent Stem Cells by Providing Genetic "Emergency Exit" Switch.Gene therapy with HSV1-sr39TK/GCV exhibits a stronger therapeutic efficacy than HSV1-TK/GCV in rat C6 glioma cells.

P2860

Q27655704-582E72F3-C0BA-4707-93D3-F4D11B4F81FB Q33428576-BA52B4B7-5F2E-4C92-BF5D-40DAA1D38A9D Q33598652-5CACBBD7-46CA-48E9-8EBC-695BBF2DD0FB Q33677054-F6A8AE63-D743-467F-A1E0-EC04C5646858 Q33730998-1DA7D857-C0A9-43C6-B28E-C60EE92FEC7D Q33855150-08A1CFA1-DC22-4101-8BA8-3D18077AA03D Q34022048-F25CEDDC-29BA-441E-84A4-3A19547E2FD2 Q34295186-82ED74A1-8770-4716-8BBE-221F0C444EF7 Q34507776-CC4B7D41-641C-4B97-A739-B894920ED3DC Q34984515-23D70210-2CC1-46D5-B9F6-10D0B580674F Q35102284-40A74E15-EC2C-4377-A689-EF67B91699B4 Q36062517-97CDE5A0-68D1-4F7B-9800-475B23C7A8B2 Q36821457-D1C573FA-2530-4370-8C0B-70F168550D94 Q36944102-21C03DD8-F86C-48CB-B17D-94B5F9314C32 Q37273666-D10E3295-D4C5-4D7F-9E22-8497CF6E5937 Q37489887-6550D540-B887-4C01-A9BF-F27C00BC5261 Q37989984-BE2DB1D1-9709-4A04-A7CD-4CDAC4D0407D Q38654411-1F63335F-E397-4235-969A-87CA3898621F Q38733802-33EA143E-CDA6-4A7C-A10B-93E41211AF29 Q38800411-6C52907F-D7B5-4AE7-9D0A-9910413D4631 Q38929123-D365D89B-24F8-4015-B22A-A6339739387A Q39064497-F675E2AE-E354-4E13-B8E1-28737144D6CA Q39516198-85A18E8F-B771-479E-B6A9-3B46FBD0281F Q40170852-F0730F2B-C2A5-4B70-AEB3-149059C523F0 Q40393182-08F286DC-8BB5-4B24-A432-3A17282AEEE8 Q40418970-4148885D-CC14-42D7-902D-E60ECCA8246D Q41589159-F731EC4E-8119-4E62-AF7D-B7C096980EA1 Q42585589-4FE1CD0A-2874-489F-98E3-D4D9DD405383 Q44061285-6B4B55BD-2FC7-44AC-BC79-7600AAE85468 Q44970732-B17A9B2E-BDCE-4D24-8C46-BFE96BFAC1A7 Q45416648-F5BA8E57-6D49-43B8-9FB9-3D744020C1F3 Q47556660-981A7705-38F8-43F2-BBB3-BE6585388BB8 Q51467919-431E298E-468D-4508-99F0-748527E61781

P2860

Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.

http://www.wikidata.org/entity/Q33184179

description

2002 nî lūn-bûn

@nan

2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Characterization of herpes sim ...... iclovir or acyclovir activity.

@ast

Characterization of herpes sim ...... iclovir or acyclovir activity.

@en

type

label

Characterization of herpes sim ...... iclovir or acyclovir activity.

@ast

Characterization of herpes sim ...... iclovir or acyclovir activity.

@en

prefLabel

Characterization of herpes sim ...... iclovir or acyclovir activity.

@ast

Characterization of herpes sim ...... iclovir or acyclovir activity.

@en

P1433

Q33184179-3D11259E-0456-47BD-A2A6-7EAF33C62663

P1476

Q33184179-79EB6778-ED7F-47E9-9596-8788E175FA16

P2093

Q33184179-6EE5476B-2B04-4B15-81C9-BC0BE323EA42

Q33184179-A08488C9-23C0-4E78-9018-75746234EA03

P2860

Q33184179-1259E8D0-1DFA-4F78-911A-43648EC0CFAD

Q33184179-15136F11-AC9F-4054-9382-F2A56C9D46A3

Q33184179-1B404EB9-9EFF-4383-85BD-055F25F86B8C

Q33184179-319CD86B-0AFE-4E5A-BD57-5086059EBCFE

Q33184179-32556850-F7FA-49CD-BEF5-A62C2B488957

Q33184179-3678E91E-DD17-4E72-85D7-A7ECE74499CA

Q33184179-3A1C0806-0926-435B-ADA1-E793E8A553DC

Q33184179-40DE4EE3-EF57-4AC5-A0A0-18F3C4D82805

Q33184179-40FD36D1-C7FE-4287-852D-CF30D9F1DB7A

Q33184179-42D83476-C93E-4432-B9F1-B55E454EA4C0

P304

Q33184179-F2451AEA-D1B4-445C-ABF5-1D59A12A3684

P31

Q33184179-980DA747-CA26-410C-AC3E-D31B5A07FEB3

P356

Q33184179-A9D05545-C618-43BE-B7F7-C6ACF00FCFD3

P433

Q33184179-BA85DC85-1C87-43F4-9680-2ADFE463842C

P478

Q33184179-4B3F3EF6-F018-4947-9231-319BD8A5B891

P577

Q33184179-FE4B6F27-F31C-4698-971B-8ABFD344F929

P5875

Q33184179-4A3DF303-142E-4043-AD7E-4F4062FFB612

P698

Q33184179-6C6F7972-221A-46CE-8209-52EFA153BDB5

P932

Q33184179-F9A4AA51-234B-489C-B3ED-5A13BED17C98

P356

P1433

Protein Science

P1476

Characterization of herpes sim ...... iclovir or acyclovir activity.

@en

P2093

Margaret E Black

http://www.w3.org/2001/XMLSchema#string

Mark S Kokoris

http://www.w3.org/2001/XMLSchema#string

P2860

Herpes simplex virus type 1 and human DNA polymerase interactions with 2'-deoxyguanosine 5'-triphosphate analogues. Kinetics of incorporation into DNA and induction of inhibition

9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication

Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase

Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant.

Permissible amino acid substitutions within the putative nucleoside binding site of herpes simplex virus type 1 encoded thymidine kinase established by random sequence mutagenesis [corrected]

The "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice.

In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy.

Viral thymidine kinases and their relatives.

Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection.

Regression of established macroscopic liver metastases after in situ transduction of a suicide gene.

P304

2267-2272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1110/PS.2460102

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11196224

http://www.w3.org/2001/XMLSchema#string

P698

12192082

http://www.w3.org/2001/XMLSchema#string

P932

2373606

http://www.w3.org/2001/XMLSchema#string